Kodiak Sciences (KOD) Other financing activities (2019 - 2026)
Kodiak Sciences' (KOD) quarterly Other financing activities came in at $922000.0 in Q1 2026, up 643.55% YoY from $124000.0 in Q1 2025, and down 99.47% on a QoQ basis from $172.9 million in Q4 2025.
Analysis
Kodiak Sciences (KOD) Other financing activities (2019 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 8 years of Other financing activities data on file, last reported at $922000.0 in Q1 2026.
- Quarterly Other financing activities rose 643.55% year-over-year to $922000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173.8 million (up 89930.05% YoY) and the FY2025 annual result came in at $173.0 million, up 161544.86% from the prior year.
- Other financing activities slipped to $922000.0 in Q1 2026, from $172.9 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $172.9 million in Q4 2025 to a low of -$1.6 million in Q2 2022.
- A 5-year average of $12.6 million and a median of $85000.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2023 — Other financing activities plunged 104.16% — and 2025, when it soared 360062.5%.
- Tracing KOD's Other financing activities over 5 years: stood at $1.7 million in 2022, then tumbled by 92.85% to $122000.0 in 2023, then slumped by 60.66% to $48000.0 in 2024, then soared by 360062.5% to $172.9 million in 2025, then plunged by 99.47% to $922000.0 in 2026.
- The last three Other financing activities figures came in at $922000.0 (Q1 2026), $172.9 million (Q4 2025), and -$42000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.86 Mn |
| Mar 31, 2026 | 922,000.00 |
| Dec 31, 2025 | 172.03 Mn |
| Sep 30, 2025 | 813,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Dec 31, 2024 | 335,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Jun 30, 2023 | 122,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Sep 30, 2022 | 90,000.00 |
| Jun 30, 2022 | 2,000.00 |
| Mar 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | 1.99 Mn |
| Sep 30, 2021 | 2.04 Mn |
| Jun 30, 2021 | 2.23 Mn |
| Mar 31, 2021 | 1.48 Mn |
| Mar 31, 2020 | 99.64 Mn |